
Four Robots, One Market: What Hugo's General Surgery Clearance Means for Hospital Robotics Strategy
Dr. Dereck Mush, MD, MBACommercial-stage medtech company pioneering pulsed electric field ablation for oncology and chronic disease.
Galvanize Therapeutics is a commercial-stage medical technology company pioneering pulsed electric field (PEF) ablation technologies for oncology and chronic disease. It is commercializing the Aliya PEF platform in the United States and advancing a pipeline that includes RheOx therapy for chronic bronchitis. On November 16, 2026, the company announced an oversubscribed $130 million Series D led by HealthQuest Capital, with Olympus Innovation Ventures and Braidwell LP joining as new investors. Proceeds will support continued commercial expansion of Aliya, clinical evidence generation, advancement of RheOx therapy for chronic bronchitis, and development of next-generation PEF products and platforms.
Chairman and Chief Executive Officer
Board member (Founder and Managing Partner, HealthQuest Capital), joining in connection with the Series D
How Galvanize Therapeutics got here, step by step.
16 November 2026
Galvanize announced an oversubscribed $130 million Series D led by HealthQuest Capital, with Olympus Innovation Ventures and Braidwell LP as new investors and participation from existing investors including Sofinnova Partners, Norwest and T. Rowe Price Associates, Inc.
16 November 2026
Galvanize Therapeutics Raises $130 Million in Oversubscribed Series D Financing16 November 2026
$130 million Series D round18 November 2026
Doug Godshall, Chairman and CEO
Dr. Dereck Mush, MD, MBAMentions Galvanize Therapeutics
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: